INTRODUCTION
T lymphocytes are heterogeneous, and a number of subpopulations have been defined phenotypically, for example, CD45RA is expressed on naïve T lymphocytes and CD45RO on memory T lymphocytes. Markers that relate more directly to function, particularly chemokine receptors and homing molecules, have subdivided memory T lymphocytes further, e.g., into those that lack CD62L and CCR7 as central (T CM ) cells and those that express them and are capable of peripheral migration, the effector memory (T EM ) populations [1] . Correlating the functional capacities of T lymphocyte subpopulations with phenotypically defined T lymphocyte subpopulations is central to our understanding of many disease processes and identifies target populations for future cell-based therapies.
The CD300 family of molecules is a group of Ig superfamily leukocyte surface molecules. At the 8th Human Leukocyte Differentiation Antigen Workshop, the CMRF-35 monoclonal antibody (mAb) was assigned to the CD300 cluster. The prototype members of this family are the CD300a (formerly CMRF-35H) and the CD300c (formerly CMRF-35A) molecules [2, 3] . We have characterized four new members of this family [4] , and these, like the prototype members CD300a and CD300c, are encoded by individual genes localized to a gene complex on human chromosome 17 [4 -8] . Each CD300 molecule has a single V-like Ig domain. CD300a and CD300c share 80% amino acid sequence similarity between their Ig domains. The functions of these molecules and their biological ligands are unknown; however, CD300a contains ITIMs in its cytoplasmic sequence, and at least one of these is functional [5] . Thus, it is likely that the CD300 family molecules are involved in the regulation of the immune response.
The CMRF-35 mAb recognizes an epitope on both CD300c and CD300a and binds to most leukocytes, including monocytes, granulocytes, dendritic cells (DC), and natural killer cells. The CMRF-35 mAb binds to a subpopulation of peripheral T lymphocytes [9] . The aim of this paper was to characterize the CD4 ϩ T lymphocyte population by their expression of the CD300 molecules. In this paper, we describe the phenotypic analysis of the peripheral CD4 ϩ T lymphocyte CMRF-35 pos population. The CMRF-35 pos CD4 ϩ T lymphocytes can be further subdivided into CMRF-35 ϩϩ , CMRF-35 ϩ , and CMRF-35 Ϫ populations, and the functional responses of these new CD4 ϩ T lymphocyte subsets were analyzed. The CMRF-35 ϩϩ CD4 ϩ T lymphocyte population regulates T lymphocyte activation, indicating the functional significance of this novel subset and the likely importance of the CD300a/c molecules in T lymphocyte homeostasis and antigenic activation.
MATERIALS AND METHODS

Samples
Fresh blood samples were obtained with consent from normal healthy donors or from buffy coats supplied through the Australian Red Cross Service (Brisbane, Australia) according to ethical guidelines approved by the Human Research Ethics Committee of the Mater Health Services. Donors were between 25 and 64 yr of age. Psoriasis samples were obtained with consent from clinically diagnosed patient donors according to ethical guidelines approved by the Human Research Ethics Committee of the Mater Health Services.
Phenotyping of T lymphocytes
Peripheral blood mononuclear cells (PBMC) were prepared by density gradient centrifugation over Ficoll-Paque Plus (Amersham Biosciences, Piscataway, NJ, USA). PBMC were labeled with CMRF-35 mAb [9] and sheep anti mouse secondary reagent (PE; Chemicon, Temecula, CA, USA, or Alexa 588, Invitrogen, Carlsbad, CA, USA) and directly conjugated CD4-PerCP, CD45RO-APC, and CD3-FITC, CD8-FITC, CD127-FITC, CD95-FITC, CLA-FITC, CD27-PE, CD38-PE, CD28-PE, CD62L-PE, CD195-FITC (BD Biosciences, San Jose, CA, USA), CXCR3-FITC or CCR7-FITC (R&D Systems, Minneapolis, MN, USA). Whole blood cells were labeled with antibodies prior to lysing red blood cells using FACS Lysing Solution (BD Biosciences). Cells were analyzed on a FACS Calibur or LSRII (BD Biosciences). Data were analyzed by gating on the CD4 ϩϩ , FSC low population of lymphocytes and excluding the CD4 ϩ , FSC high monocyte population.
Quantitative analysis of CMRF-35 binding to CD4 ϩ T lymphocytes
Quantitation of the levels of CMRF-35 binding to isolated CD4ϩ T lymphocytes was performed using a QIFKIT cytometric quantitation kit (DAKO), according to the manufacturer's recommendations.
Isolation of CD4
ϩ T lymphocytes CD4 ϩ T lymphocytes were purified from PBMC using Human CD4 ϩ T cell enrichment cocktail (StemCell Technologies) and a modified protocol [10] . CD4 ϩ T lymphocytes were Ͼ95% pure. Purified CD4 ϩ T lymphocytes were labeled with CMRF-35 mAb followed by sheep anti mouse secondary reagent and the CMRF-35 ϩϩ , CMRF-35 ϩ, and CMRF-35 Ϫ populations were selected on a FACS ARIA (BD Biosciences). Fab fragments of the CMRF-35 mAb were prepared using an ImmunoPure Fab Preparation Kit, according to the manufacturer's protocol (Pierce Biotechnology, Rockford, IL, USA). These were directly conjugated to FITC and used to sort the CD4 ϩ T lymphocyte populations.
Allogeneic mixed leukocyte reactions
HLA-DR
ϩ Lin -DC were purified from PBMC as described by Osugi et al. [11] . Cell purity was routinely greater than 95%. For some experiments, BDCA-1 ϩ DC were prepared using positive selection, according to the manufacturer's recommendations (Miltenyi-Biotec). Allogeneic mixed leukocyte reactions (MLRs) were established using 5 ϫ 10 4 HLA-DR ϩ Lin -cells or irradiated BDCA-1 ϩ DC, cultured with 10 5 allogeneic T cells that had been sorted into different subpopulations by CMRF-35 labeling, in complete RPMI 1640 media (RPMI 1640 containing 10% FCS, 100 U/ml penicillin, 100 g/ml streptomycin, 2 mM glutamine, 10 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid) solution (Invitrogen), 50 M mercaptoethanol (Sigma, St. Louis, MO, USA) at 37°C in 5% CO 2 for 5 days. T cell proliferation was measured by [ 3 H]-thymidine uptake (1 Ci/well; 6.7 Ci/mM; Amersham Biosciences). Responses are reported as mean cpm Ϯ SEM for triplicate wells.
Proliferation assay
T lymphocytes, 2 ϫ 10 5 purified cells/well, were stimulated either with 30 m PMA and 0.5 M ionomycin or immobilized CD3 (10 g/ml) and CD28 (10 g/ml) [12] for 5 days. Proliferation was assessed by [ 3 H]-thymidine uptake (1 Ci/well). Following stimulation, cells were analyzed for CD25 and CD69 up-regulation, cytokine synthesis, or induction of apoptosis. Alternatively, sorted T lymphocyte populations were labeled with CFSE and cultured with Dynabeads CD3/CD28 T cell expander (Dynal Biotech, Oslo, Norway) for up to 72 h. In some experiments, anti-human IFN-␥ mAb (B27 clone; BD PharMingen, San Jose, CA, USA) was added to neutralize secreted IFN-␥.
Tetanus toxoid recall response
Purified T lymphocytes (5ϫ10 4 per well) and autologous PBMC (2ϫ10 4 per well, irradiated at 3000cGy) were incubated at a ratio of 2.5:1 (responder: stimulator) ratio. Tetanus toxoid (TT) was added at a concentration of 20 g/ml. Following 5 days of culture, the lymphocytes' proliferation was assessed by the addition of [ 3 H]-thymidine (1 Ci/well) 16 h before harvesting.
Cytokines analysis
To determine intracellular cytokine production by flow cytometry, cells were incubated with Golgi Plug (PharMingen, San Jose, CA) before labeling with IL-10-PE, IL-4-PE, and IFN-␥-FITC or IFN-␥-PE (PharMingen) using a Fix/Perm Kit (Caltag Laboratories).
Analysis of apoptosis
Apoptosis was assessed on 1 ϫ 10 5 -1 ϫ 10 6 cells stained with Annexin V-EGFP (Clontech) and propidium iodide, at RT for 15 min in the dark before analysis on a FACS Calibur.
Real-time RT-PCR analysis
Total RNA was prepared using Trizol reagent (Invitrogen), treated with DNase I (Invitrogen), and transcribed into cDNA using Superscript III Platinum Two-Step qPCR kit (Invitrogen). Polymerase chain reaction (PCR) amplification for each cytokine used primers designed by Kruse et al. [13] . PCR standards for each cytokine consisted of known numbers of molecules of purified PCR product [14] . The primer and probe sequences for real-time PCR were ubiquitin converting enzyme (UCE)-forward: TGAAGAGAATCCACAAGGAATTGA, UCE-reverse: CAACAGGACCTGCTGAACACTG, UCE-probe: TGATCTGGCACGGGAC-CCTCCA [10] , CD300a-forward: CCTGCACAACAGTGACCAAC, CD300a-reverse: CTGATGGCAACAGAGGGAT, CD300a-probe: TGGGAAACCCAGCT-GCCTGTC, CD300c-forward: TGTCGCTATGAGAAGGA, CD300c-reverse: TGT-CACATCGGAGAATC, CD300c-probe: CAGGACCCTCAACAAATTCTGGTGC, IFN-␥-forward: AATAGCAACAAAAAGAAACGAGATGA, IFN-␥-reverse: TG-TATTGCTTTGCGTTGGACA [15] , IL-2-forward: TGCATTGCACTAACTCTTGC, IL-2-reverse: CAGCAGTAAATGCTCCAGTTG, and IL-2-probe: TGTCACAAA-CAGTGCACCTACTTCAAGTTC [16] . Real-time PCR probes were labeled with 5Ј-Fam and 3Ј-BHQ1, (Biosearch Technologies, Novato, CA, USA). Reactions were prepared using Platinum Quantitative PCR SuperMix-UDG and Platinum Taq DNA polymerase. Amplification was performed on a Rotor-Gene 3000 (Corbett Research, Sydney, Australia). Data were analyzed using Rotor-Gene 6.0 software and REST2000 [17] . Data were normalized to the level of UCE.
Statistical analysis
One way ANOVA was performed on pooled data from multiple experiments. Comparisons between two groups were performed by two-tailed paired Student's t test. Mann-Whitney t test was used to analyze binding of CMRF-35 to CD4ϩ T cells in normal and psoriasis donors. P Ͻ 0.05 was considered significant. Statistical analysis was performed using GraphPad Prism software (GraphPad Prism, San Diego, CA, USA).
RESULTS
Peripheral blood T lymphocytes express different levels of CD300a and CD300c
The CMRF-35 mAb binds CD300a and CD300c [2] . We have previously shown that CMRF-35 binds to between 79.1 and 90.5% (83.45Ϯ5.1%, nϭ7) of normal peripheral blood CD3 ϩ cells [9] . The CMRF-35 mAb bound to 86.9Ϯ5.5% (nϭ10) of CD8 ϩ lymphocytes but to a lesser proportion (56.2 Ϯ 16%, nϭ28 with a range of 89.9 to 26.9, Fig. 1C (Fig. 1C) , accounting for ϳ21.7 Ϯ 10%, 34.04 Ϯ 12.4%, and 19.6 Ϯ 10.6% of the cells, respectively (the intervening CMRF-35 dim cells were excluded to ensure the purity of the flow cytometry gated populations (Fig. 1D) . By including CD45RO in the analysis, the CD4 ϩ T lymphocytes were subdivided further into five distinct populations (Fig. 1E, F) . The CD45RO ϩ CD4 ϩ subset contained most of the CMRF-35 ϩϩ cells with 53.6 Ϯ 23% labeled with CMRF-35 mAb, whereas 69.7 Ϯ 16% of the CD45RA ϩ naïve CD4 ϩ T lymphocytes expressed the CMRF-35 epitope but with lesser density (Fig.  1E ). This division into five distinct CD4 subpopulations on the basis of the flow cytometry dot plot labeling patterns (Fig. 1F ) was consistent over the 28 donors. The phenotype analysis between whole blood and PBMC was compared ( Fig. 2A, B) .
The pattern of CMRF-35 binding to CD4
ϩ CD45RO ϩ lymphocytes was similar, however, there appeared to be a slight variation in the MFI, with the PBMC fraction showing marginally increased intensity of staining with the CMRF-35 mAb. We performed repeat phenotyping on three normal donors and found that the CD4 ϩ
CMRF-35
ϩ T lymphocyte populations appeared to be stable, that is, were similar in these healthy individuals over at least three months (Fig. 2C, D) . As the CMRF-35 ϩϩ T lymphocytes were found in the CD45RO memory population and the CMRF-35 ϩ cells were found mainly in the naïve CD45RO
-T lymphocyte population, we assessed the binding of the CMRF-35 mAb to naïve cord blood CD4 ϩ T lymphocytes and tonsil CD4 ϩ T lymphocytes. Most cord blood CD4 ϩ lymphocytes bound CMRF-35 mAb at low levels, and only a small population of CMRF-35 -CD4 ϩ T lymphocytes was identified (data not shown). Tonsil CD4 ϩ lymphocytes showed high, medium, and low levels of CMRF-35 binding. Thus, the CMRF-35 detected a pattern of CD300a/c expression, which differs between naïve and experienced CD4 ϩ T lymphocytes, 
CD45RO
ϩ T lymphocyte populations that remain stable in the absence of disease.
Separation of CD4
ϩ T lymphocytes into CMRF-35 ϩϩ , CMRF-35 ϩ , and CMRF-35 -populations CD4 ϩ T lymphocytes were purified by negative selection and labeled with the CMRF-35 mAb followed by sheep anti mouse PE. FACS analysis of these samples enabled discrimination of the three populations as shown in Fig. 3A . The level of CMRF-35 binding to the CMRF-35 ϩϩ population was 10-fold higher and 100-fold higher than to the CMRF-35 ϩ and CMRF-35 Ϫ populations, respectively, as quantified cytometrically using the QIFKIT.
Expression of CD300a and CD300c genes in the CD4
ϩ populations
As the CMRF-35 mAb binds to both CD300a and CD300c, we used RT-PCR to investigate their mRNA expression in the CD4 ϩ T lymphocyte populations. Although both the CD300a and CD300c genes are expressed by resting CD4 ϩ T lymphocytes, CD300c was expressed at much lower levels relative to control UCE expression (Fig. 3B) . Purified CMRF-35 ϩϩ CD4 ϩ T lymphocytes expressed high levels of CD300a mRNA, with lower levels expressed in the CMRF-35 ϩ CD4 ϩ T lymphocytes, consistent with the surface antigen density. Activation of CD4 ϩ T lymphocytes with CD3/CD28 beads produced in an initial down-regulation of CMRF-35 binding at 48 h, followed by increased surface staining at 72 h (Fig. 4A) . This was reflected in an initial down-regulation of both CD300a and CD300c gene expression at 24 h followed by re-expression at 48 h (Fig. 4B) . These results indicate that subpopulations of peripheral CD4
ϩ T lymphocytes express the inhibitory molecule CD300a and that activation of these cells almost certainly up-regulated the surface expression of both the CD300a and CD300c gene products.
Phenotype of resting peripheral blood T lymphocyte defines a new T lymphocyte subset
The CD4
ϩ CD45RO ϩ/Ϫ T lymphocyte populations were then phenotyped in greater detail (Fig. 5) 
CD3
ϩ or unseparated CD3 ϩ T lymphocyte The addition of exogenous IL-2 did not allow recovery of the CMRF-35 pos population from proliferation in response to PMA/ ionomycin (Fig. 6D) ϩ T lymphocytes were used as responders. Very little IL-4 mRNA was produced in these MLR samples, although there was some IL-10 produced (data not shown).
The results of the RT-PCR cytokine assays were confirmed by intracellular labeling. Purified CMRF-35 ϩ/ϩϩ CD4 ϩ and CMRF-35 -D4 ϩ populations of CD4 ϩ T lymphocytes were activated in vitro with PMA/ionomycin and were assayed for intracellular IL-4, IL-10, or IFN-␥. Neither IL-4 nor IL-10 was detected in any in vitro activated population by intracellular labeling (data not shown). Following activation for 4 h with PMA/ionomycin, the CMRF-35 -CD4 ϩ population expressed little intracellular IFN-␥ but a subpopulation of the CMRF-35 pos CD4 ϩ T lymphocyte population had readily detectable cytokine (Fig. 8A) .
Proliferation resulted with the CMRF-35 -CD4 ϩ population and to a lesser extent in the CMRF-35 ϩ CD4 ϩ population but again the CMRF-35
ϩϩ CD4 ϩ population did not proliferate in the absence of recall antigen. These results indicate that the CMRF-35 ϩϩ CD4 ϩ T lymphocyte subpopulation contains the effector memory cells that respond with IFN-␥ production but do not proliferate, unless exposed to specific antigen. 
CD4
ϩ T lymphocytes were stained with annexin V-EGFP and propidium iodide to assess apoptosis. Following in vitro activation with CD3/CD28, the CMRF-35 ϩϩ CD4 ϩ T lymphocyte population was clearly more susceptible to apoptosis, even after four hours of activation (Fig. 8B) . The CMRF-35 ϩϩ subpopulation secreted the majority of the IFN-␥ within CD4 ϩ T lymphocyte. Others have shown that IFN-␥ is implicated in activation-induced cell death [18] . To investigate whether the secreted IFN-␥ contributed to the apoptosis and lack of proliferation of the CMRF-35 ϩϩ population, in the absence of recall antigen, we retested the activation of the CMRF-35-defined subpopulations, in the presence of an IFN-␥ neutralizing mAb. Rapid cell death was still observed despite the presence of an effective concentration (10 g/ml) of neutralizing anti-IFN [18] ␥ mAb. Thus, it appears that the IFN-␥ produced by the CMRF-35 ϩϩ CD4 ϩ T lymphocyte subpopulation was not responsible; instead it appears that the lack of a specific recall antigenic stimulus allows apoptosis to proceed in these effector memory cells.
The CMRF-35
lymphocyte population is altered in psoriasis
The novel CD4 ϩ T lymphocyte subpopulations defined by CMRF-35 mAb were stable in normal steady state conditions but to examine their potential modification by sustained immune perturbation, we screened a group of patients with the Th 1 -mediated chronic inflammatory disease, psoriasis. In some, but not all, samples tested (nϭ36), we found that the profiles of CMRF-35 mAb labeling of CD45RO ϩ CD4 ϩ T lymphocytes was altered (Fig. 9A) . The analysis of peripheral blood samples from psoriasis patients showed that there was a significant reduction in the binding of CMRF-35 mAb to CD45RO ϩ CD4 ϩ memory T lymphocytes in patients compared with a cohort of normal controls, (Fig. 9, Pϭ0.04) . Removal of patients on systemic treatment at the time of analysis from mAb on the gated CD4 ϩ T lymphocyte subpopulation of this patient, which differs from normals (Fig. 3). (B 
CD4
ϩ subpopulations. The data presented here provide initial evidence that these are novel subpopulations, distinct from the currently defined naïve and memory populations and that they are relevant, both in the steady state, and for further investigation in human disease. Most notably, the CMRF-35 ϩϩ CD4 ϩ T lymphocyte subpopulation expressed IFN-␥ mRNA spontaneously and early after activation but only proliferated in response to the recall antigen TT, being hypoproliferative and prone to apoptosis in response to independent stimuli. We monitored the expression of CD300a, which has cytoplasmic ITIMs and also CD300c, which is anticipated to partner with an ITAM signaling molecule in CD4 ϩ T lymphocytes from cord blood, adult peripheral blood, and tonsil. Only a low level of CMRF-35 binding to cord blood CD4 ϩ T lymphocytes was noted, and CD300a/c expression was up-regulated on tonsils from children and peripheral blood lymphocytes in adults. The CD300a molecule was present on both the CMRF- ϩϩ population could be further divided phenotypically on the expression of the same lymph node or tissue homing receptors used to define memory cells, effector functions, proliferative capacity, and responses to homeostatic cytokines [19] . T EM (effector memory) cells have down-regulated the CCR7 and CD62L lymph node homing receptors and are primed to respond to antigen stimulation [1] . Others have suggested that antigen-specific memory T cells are present in alternatively defined memory subsets, which depend on the nature of the immune response generated [20] . In our experiments, we localized the memory response to TT within the CMRF-35 ϩϩ and not the CMRF-35 -CD45RO ϩ CD4 ϩ T lymphocyte population, allowing further subdivision of memory cell function. Interestingly, these cells did not proliferate in response to antigen-independent (PMA/ionomycin) stimulation, reflecting the different signals involved and the effects of the antigen-presenting cells on CD4 memory responses [21] .
The differentiation of memory CD4 T cells has been suggested to proceed through stages, allowing three sequential populations to be defined by the CCR7 The decreased proliferative response to antigen-independent stimulation and increased IFN-␥ production by the CMRF-35 ϩϩ CD4 ϩ T lymphocyte population, in response to activation was associated with a significant increase in apoptosis, that was not observed with the other populations. The CMRF-35 -
ϩ T lymphocyte population showed normal proliferation, little IFN-␥ production, less annexin V staining, and less surface Fas ligand (CD95). IFN-␥ is required for activationinduced cell death [18] and for the induction of CD95 [25] . Thus T cell homeostasis is in part controlled by IFN-␥, which limits T cell expansion by reducing survival rather than inhibiting cell cycle progression [18] . We have shown here that the CMRF-35 mAb identifies a population of CMRF-35 ϩϩ CD4 ϩ T lymphocytes, which undergoes increased apoptosis and IFN-␥ production in response to antigen-independent activation signals. This makes these cells more susceptible to apoptosis in the absence of specific recall antigen exposure. Our data appeared to exclude a contribution from the IFN-␥ to this apoptotic process, as neutralizing mAb did not prevent it. We, therefore, favor the view that the IFN-␥-secreting capacity of these cells relates to their capacity to respond rapidly, when exposed to antigen and that it also acts as a protective homeostatic mechanism to control their proliferation in the absence of specific antigen. It is even possible that it is the failure of such mechanisms that contribute to inflammatory/autoimmune diseases, and hence, the reduced presence of this population that we noted in psoriasis, perhaps reflecting their migration to the tissues, is most interesting. This CMRF-35 ϩϩ CD4 ϩ T lymphocyte population that can now be defined in normal human peripheral blood is similar to the population of Th 1 lineage cells defined by IFN-␥ production described in mice by Wu and colleagues [26] . They showed these Th 1 cells to include short-lived IFN-␥-secreting cells that, likewise, underwent apoptosis but not via an IFN-␥-dependent mechanism.
It is likely that the clinical relevance of the novel T lymphocyte populations extends to other autoimmune/inflammatory diseases and transplantation interactions. We have not attempted as yet to investigate the possibility that Th 1 or Th 2 responses may be differentially expressed in these novel populations, given that this depends considerably on the stimulators used. At face value, the CMRF-35 ϩϩ IFN-␥ production population response appear to be Th 1 on the basis of their IFN-␥ production (and their failure to produce IL-4). Changes in either the function or the frequency of this novel IFN-␥ producing CD4
ϩ T lymphocyte population and the other populations defined by CD300a/c expression in other autoimmune diseases is being assessed. In the primary immune response, T cells are activated in an antigen-specific manner and, once activated, nonspecific activation through bystander activity is potentially dangerous. Our experiments appear to have revealed an important functional mechanism, at least for the CMRF-35 ϩϩ subpopulation of memory cells: these appear to be programmed to die rapidly following nonspecific activation but are able to respond to specific recall antigen with prompt CD25 expression and IL2 production (given the lack of effect of additional IL-2) and to proliferate.
Discerning the molecular mechanism involved will be complex, but presumably, it relates to the new signaling networks established in naïve cells after their first exposure to specific antigen triggering via an antigen-presenting cell. The CD300a molecule itself may contribute to this by its ITIM motifs down-modulating the threshold for triggering a T lymphocyte response.
In summary, the CMRF-35 mAb defines novel CMRF-35 -CD4 ϩ , CMRF-35 ϩ CD4 ϩ and CMRF-35 ϩϩ CD4 ϩ T lymphocyte subpopulations. The latter includes the major IFN-␥-secreting CD4 ϩ cell subset and the cells that respond to the recall antigen TT. This population also has the novel functional capacity to self-regulate its response to nonspecific antigen and induces an apoptotic process that may be designed to avoid inappropriate bystander autoimmune activation. The functional capacities of these new subpopulations will require much more investigation, but our initial data suggesting that these new subpopulations are altered substantially in psoriasis, suggests that the data may have considerable relevance.
